| Title: | Encysive Pharmaceuticals Inc. at JPMorgan 25th Annual Healthcare Conference Transcript |
| Price: | $54.00 |
| Publication Date: | Jan 11, 2007 |
| Source: | Thomson StreetEvents |
| Report Type: | Transcript |
| Abstract: | Final Transcript of ENCY presentation, 11-Jan-07 10:30am PT |
| Brief Excerpt: | ... - JPMorgan - Biotechnology Analyst Good morning. Welcome to the last day of the JPMorgan Healthcare conference. I'm Geoff Meacham, Biotechnology Analyst here at JPMorgan. It is my pleasure to introduce Encysive Pharmaceuticals, one of the leading companies in the pulmonary hypertension space anchored by THELIN, which is approved in Europe and awaiting approval at the FDA. Also, TBC####, a drug in clinical development for resistant hypertension, rounds out the pipeline there. And speaking on behalf of Encysive is CEO Dr. Bruce Given. ... |
| Word Count: | 4555 |
| Length: | 7 Pages |
| Ticker: | ENCY |
| Time: | 10:30am PT |
| Related Report(s): | |
| Format: |
Adobe Acrobat
|
| Free Sample: |
Click
Here
to Download
|
Looking For Something Else?